What Does Survival Look Like After Proton Therapy, as of 2026?

There is no standalone survival statistic for proton therapy itself. Survival rates are more accurately checked as national statistics by cancer type and stage, not by treatment method. For example, the 5-year relative survival rate for prostate cancer in Korea is 96.9% (National Cancer Registration Statistics, 2019–2023).

Key Takeaways

• Proton therapy is classified as a type of particle radiation therapy. Its biological effect on cancer cells is similar to conventional X-ray radiation; its advantage lies in causing less damage to surrounding healthy tissue.
• Survival rates are not tracked for "people who received proton therapy" specifically, but rather compiled as national statistics by cancer type and stage. For example, the 5-year relative survival rate for prostate cancer is 96.9% (National Cancer Registration Statistics, 2019–2023), up 37.7 percentage points from 1993–1995.
• Proton therapy is primarily used for pediatric cancers, tumors near the eyes, brain, spinal cord, and skull base, as well as localized or locally advanced tumors such as hepatocellular carcinoma and some lung and esophageal cancers. Widely metastatic cancer is not a standard indication.
• Treatment response is assessed through imaging over several months after treatment ends, and individual outcomes vary depending on stage, tumor location, age, and prior treatment history.
• Survival rate figures are national statistics, not the performance results of any specific hospital. Under Korean medical law, individual hospitals are not permitted to publish their own outcome statistics on public pages.

Does proton therapy help people live longer?

• There is no figure indicating that proton therapy directly extends survival time. The role of proton therapy is described as delivering the same radiation dose to the tumor while reducing the dose to surrounding healthy tissue. The biological effect of killing cancer cells is described as similar to that of conventional X-ray radiation.
• Therefore, if you need survival figures, you should look at national statistics for the specific cancer type and stage rather than whether proton therapy was used. For example, the 5-year relative survival rate is 96.9% for prostate cancer, 78.6% for stomach cancer, 75.6% for colorectal cancer, and 94.7% for breast cancer (National Cancer Registration Statistics, 2019–2023). These figures are all national population averages and are not predictive of any individual's outcome.

When is proton therapy used?

• First, pediatric cancers. Since radiation exposure to healthy tissue in a growing body must be minimized as much as possible, children are a representative target population. Second, tumors adjacent to structures that are difficult to repair if damaged—the eyes, brain, spinal cord, and skull base (head and neck cancers, brain tumors, chordoma, ocular melanoma, etc.). Third, localized tumors where surrounding healthy organs must be protected, such as hepatocellular carcinoma and some lung and esophageal cancers. Fourth, cases of recurrence in an area previously treated with radiation, where re-irradiation needs to be considered.
• Cancers that have spread to multiple organs, or blood cancers, are not a standard indication for proton therapy. In metastatic cases, systemic treatment takes priority, and proton therapy is not the first choice even for symptom palliation.

What does the treatment process and follow-up look like?

• Stage 1: Simulation imaging, fabrication of an immobilization device, and treatment planning/verification take 1–2 weeks.
• Stage 2: Treatment is delivered on an outpatient basis 5 times a week, for a total of 10–35 sessions, with each visit lasting around 30 minutes.
• Stage 3: Because of the number of sessions, total stay is typically planned at 4–7 weeks. Whether the course is short (as with prostate cancer) or spans several weeks (as with head and neck cancer) is confirmed in the written opinion.
• Stage 4: Return home is possible within a few days after the final session, and treatment response is assessed through imaging over the following months.
• Stage 5: For pediatric patients, growth and hormonal function must be monitored over the long term, so a follow-up plan to be handed off to local medical staff is documented in the handover summary.

FAQ — Are side effects unrelated to survival?

There is no pain during treatment sessions. Common reactions include fatigue and skin changes at the treatment site. Depending on the treatment area, side effects may include hair loss (head), mouth sores and dry mouth (head and neck), swallowing difficulty and coughing (chest), or changes in urination and bowel function (pelvis), most of which resolve over several weeks after treatment ends. These side effects are described as quality-of-life factors after treatment, separate from survival rate figures.

FAQ — Is there a survival difference between proton therapy and surgery for prostate cancer?

Prostate cancer treatment decisions are based on risk classification—low, intermediate, or high risk. For intermediate-risk disease, both surgery and radiation therapy (including consideration of proton therapy) are presented as standard options, and the choice is often explained as depending more on the nature of side effects—such as urinary incontinence or sexual dysfunction—than on differences in outcomes. According to national statistics, the 5-year relative survival rate for prostate cancer is 96.9% (National Cancer Registration Statistics, 2019–2023), a figure that combines surgical and radiation treatment groups rather than separating them.

Sources and Notes

• This article was written based on notes covering proton therapy, prostate cancer, stomach cancer, colorectal cancer, breast cancer, and frequently asked questions (National Cancer Registration Statistics 2019–2023 / National Cancer Center Korea's Central Cancer Registry, NCCN patient guidelines, SEER).
• This content is intended to provide general medical information. Diagnosis, treatment methods, and outcomes may vary depending on individual condition. Please consult with a medical professional to determine the appropriate diagnosis and treatment for your specific situation.